Skip to main content

Tekmira Cleared to Begin Second Phase I Trial of siRNA Cancer Drug


Tekmira Pharmaceuticals this week announced that it has received approval from the US Food and Drug Administration to go forward with a new phase I study of its siRNA-based cancer drug TKM-PLK1 in collaboration with the National Cancer Institute.

Tekmira moved the drug, which targets polo-like kinase 1, into phase I testing early this year (GSN 1/6/2011). The company said that the new study, which will be conducted in parallel with the ongoing trial, will provide an “early opportunity to validate the drug's mechanism of action.”

"Patients in this new study, who will have either primary liver cancer or liver metastases, will receive TKM-PLK1 delivered directly into the liver via hepatic artery infusion,” Tekmira Preisdent and CEO Mark Murray said in a statement. “The trial design will allow us to measure tumor delivery, polo-like kinase 1 messenger RNA knockdown, and RNA interference activity in tumor biopsies from all of the patients treated.”

Interim phase I data on TKM-PLK1 is expected before year end.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.